NEW YORK (360Dx) – Klaris Diagnostics today announced the completion of a $3.75 million Series A financing round to support continued development of its rapid antibiotic susceptibility testing platform.
The financing was led by Omnimed Capital.
Klaris is a privately held in vitro diagnostic firm developing technology to help hospitals battle antibiotic resistance. Its platform is based on its patented phenotypic single-cell technology that can rapidly identify pathogens and determine their response to antibiotics without the need for culturing. According to the firm, the system's pathogen identification and antibiotic susceptibility capabilities are integrated seamlessly due to its use of the same phenotypic method.
"With the rise of multidrug-resistant bacteria, we need solutions that will allow hospitals to safely cure and prevent antibiotic-resistant infections," Klaris CEO and Cofounder Nicolas Arab said in a statement. "Klaris has developed a groundbreaking technology that addresses this problem."
Klaris was founded in 2016 and is based in Austin, Texas.